COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA

Krantz, M.S. and Phillips, E.J. (2022) COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA. The Lancet Infectious Diseases . In Press.

Abstract

A primary mission of the US vaccination campaign, which began in December, 2020, following emergency use authorisation (EUA) of the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 mRNA vaccines, was ensure vaccine benefit while monitoring vaccine safety.(1, 2)

This mission was facilitated by both the enormity of the roll-out and mRNA COVID-19 vaccine distribution and the administration by the US Government of all doses, giving an unprecedented opportunity to measure vaccine safety. As of Feb 28, 2022, over 530 million doses of mRNA COVID-19 vaccines had been administered in the USA.

In The Lancet Infectious Diseases, Hannah Rosenblum and colleagues (3) from the US Centers for Disease Control and Prevention report the first 6 months (Dec 14, 2020, to June 14, 2021) of safety monitoring of mRNA COVID-19 vaccines, in individuals aged at least 16 years, during which time over 50% of the eligible US population received at least one vaccine dose and more than 298 million doses were administered.

Item Type:	Journal Article
Murdoch Affiliation(s):	Institute for Immunology and Infectious Diseases
Publisher:	Elsevier Ltd
Copyright:	© 2022 Elsevier Ltd.
URI:	http://researchrepository.murdoch.edu.au/id/eprint/64412

Item Control Page